Pauliina Molander

756 total citations
20 papers, 489 citations indexed

About

Pauliina Molander is a scholar working on Epidemiology, Genetics and Surgery. According to data from OpenAlex, Pauliina Molander has authored 20 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 16 papers in Genetics and 8 papers in Surgery. Recurrent topics in Pauliina Molander's work include Microscopic Colitis (16 papers), Inflammatory Bowel Disease (16 papers) and Eosinophilic Esophagitis (5 papers). Pauliina Molander is often cited by papers focused on Microscopic Colitis (16 papers), Inflammatory Bowel Disease (16 papers) and Eosinophilic Esophagitis (5 papers). Pauliina Molander collaborates with scholars based in Finland, Sweden and United States. Pauliina Molander's co-authors include Taina Sipponen, Kaija‐Leena Kolho, Martti Färkkilâ, Harri Mustonen, Johanna Haapamäki, Airi Jussila, Helena Kemppainen, Matti Vauhkonen, Clas-Göran af Björkesten and Timo Blomster and has published in prestigious journals such as Gastroenterology, Inflammatory Bowel Diseases and Scandinavian Journal of Gastroenterology.

In The Last Decade

Pauliina Molander

19 papers receiving 483 citations

Peers

Countries citing papers authored by Pauliina Molander

Since Specialization

Citations

This map shows the geographic impact of Pauliina Molander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pauliina Molander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pauliina Molander more than expected).

Fields of papers citing papers by Pauliina Molander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pauliina Molander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pauliina Molander. The network helps show where Pauliina Molander may publish in the future.

Co-authorship network of co-authors of Pauliina Molander

This figure shows the co-authorship network connecting the top 25 collaborators of Pauliina Molander. A scholar is included among the top collaborators of Pauliina Molander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pauliina Molander. Pauliina Molander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment 2024 ·Heliyon ·Tero Ylisaukko‐oja, Clas-Göran af Björkesten, (unknown), (unknown), Airi Jussila, Pauliina Molander, Ritva Koskela, Timo Blomster, (unknown), Tuire Ilus, Paula Haiko, (unknown), (unknown), Sarah Smith, Jari Jokelainen, Taina Sipponen	1
2	The need for surgery in pediatric patients with inflammatory bowel disease treated with biologicals 2024 ·International Journal of Colorectal Disease ·Kaija‐Leena Kolho, (unknown), Laura Merras‐Salmio, Pauliina Molander	0
3	Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study 2023 ·Scandinavian Journal of Gastroenterology ·Pauliina Molander, (unknown), (unknown), Jyrki Tillonen, Aki Juhani Käräjämäki, Markku Heikkinen, (unknown), Riikka Mattila, Iiro Toppila, (unknown), Kirsi Kalpala, Dan Henrohn, Clas-Göran af Björkesten	2
4	Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia 2022 ·Scandinavian Journal of Gastroenterology ·(unknown), Jørgen Jahnsen, Jørn Brynskov, Pauliina Molander, Michael Eberhardson, Lóa Davíðsdóttir, Taina Sipponen, Henrik Hjortswang, Guro Løvik Goll, Silje Watterdal Syversen, Ebbe Langholz, Kristin Kaasen Jørgensen, Casper Steenholdt	5
5	Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View 2021 ·Inflammatory Bowel Diseases ·Marla C. Dubinsky, Kenji Watanabe, Pauliina Molander, Laurent Peyrin‐Biroulet, Michele Rubin, Gil Melmed, J. Jasper Deuring, John Woolcott, Joseph C. Cappelleri, Kathy Steinberg, Susan J. Connor	32
6	Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey 2021 ·Therapeutic Advances in Gastroenterology ·(unknown), Renáta Bor, (unknown), Anna Fábián, Mariann Rutka, M. Sacco, Davide Giuseppe Ribaldone, Pauliina Molander, Stéphane Nancey, Uri Kopylov, Stephan R. Vavricka, David Drobne, Milan Lukáš, Klaudia Farkas, Zoltán Szepes, Tamás Molnár	1
7	Long-term outcomes of multimodal rehabilitation in primary care for patients with chronic pain 2020 ·Journal of Rehabilitation Medicine ·(unknown), Paul Enthoven, Björn Gerdle, Pauliina Molander, Britt‐Marie Stålnacke	18
8	Impact of ulcerative colitis on patients’ lives: results of the Finnish extension of a global ulcerative colitis narrative survey 2019 ·Scandinavian Journal of Gastroenterology ·Pauliina Molander, (unknown)	4
9	P005 DELAY IN DIAGNOSIS OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY 2019 ·Gastroenterology ·Alessandro Armuzzi, (unknown), Remo Panaccione, Kenji Watanabe, Pauliina Molander, David T. Rubin, Laurent Peyrin‐Biroulet, Gil Melmed, Susan J. Connor, Jean‐Frédéric Colombel, Marla Dubinsky	2
10	Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn’s disease: retrospective multi-centre chart review study 2019 ·Scandinavian Journal of Gastroenterology ·Clas-Göran af Björkesten, Airi Jussila, Helena Kemppainen, Taru Hallinen, Erkki Soini, (unknown), (unknown), (unknown), R Nissinen, (unknown), Pauliina Molander	1
11	Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases 2019 ·Scandinavian Journal of Gastroenterology ·Pauliina Molander, Helena Kemppainen, Tuire Ilus, Taina Sipponen	9
12	N017 The impacts of an inflammatory bowel disease nurse specialist on quality of care and costs in Finland 2018 ·Journal of Crohn s and Colitis ·(unknown), Airi Jussila, Kaija‐Leena Kolho, Pauliina Molander	1
13	P224 Relationship of faecal calprotectin and long-term outcomes in Finnish adult patients with Crohn’s disease: Retrospective multi-centre chart review study 2018 ·Journal of Crohn s and Colitis ·Taru Hallinen, Airi Jussila, Clas-Göran af Björkesten, Helena Kemppainen, Erkki Soini, (unknown), (unknown), (unknown), R Nissinen, Pauliina Molander	1
14	The impacts of an inflammatory bowel disease nurse specialist on the quality of care and costs in Finland 2018 ·Scandinavian Journal of Gastroenterology ·Pauliina Molander, Airi Jussila, (unknown), (unknown), (unknown), Kaija‐Leena Kolho	17
15	Do pain characteristics guide selection for multimodal pain rehabilitation? 2017 ·Journal of Rehabilitation Medicine ·Paul Enthoven, Pauliina Molander, Birgitta Öberg, Britt‐Marie Stålnacke, Georg Stenberg, Björn Gerdle	9
16	Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents 2016 ·Scandinavian Journal of Gastroenterology ·Pauliina Molander, Martti Färkkilâ, Helena Kemppainen, Timo Blomster, Airi Jussila, Harri Mustonen, Taina Sipponen	13
17	Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? 2014 ·Journal of Crohn s and Colitis ·Pauliina Molander, Martti Färkkilâ, Ari Ristimäki, Kimmo Salminen, Helena Kemppainen, Timo Blomster, Ritva Koskela, Airi Jussila, Henna Rautiainen, Markku Nissinen, Johanna Haapamäki, Perttu Arkkila, Urpo Nieminen, Juha Kuisma, (unknown), Kaija‐Leena Kolho, Harri Mustonen, Taina Sipponen	83
18	Outcome After Discontinuation of TNFα-blocking Therapy in Patients with Inflammatory Bowel Disease in Deep Remission 2014 ·Inflammatory Bowel Diseases ·Pauliina Molander, Martti Färkkilâ, Kimmo Salminen, Helena Kemppainen, Timo Blomster, Ritva Koskela, Airi Jussila, Henna Rautiainen, Markku Nissinen, Johanna Haapamäki, Perttu Arkkila, Urpo Nieminen, Juha Kuisma, (unknown), Kaija‐Leena Kolho, Harri Mustonen, Taina Sipponen	58
19	Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD 2012 ·Journal of Crohn s and Colitis ·Pauliina Molander, Taina Sipponen, Helena Kemppainen, Airi Jussila, Timo Blomster, Ritva Koskela, Markku Nissinen, Henna Rautiainen, Juha Kuisma, Kaija‐Leena Kolho, Martti Färkkilâ	88
20	Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents 2012 ·Inflammatory Bowel Diseases ·Pauliina Molander, Clas-Göran af Björkesten, Harri Mustonen, Johanna Haapamäki, Matti Vauhkonen, Kaija‐Leena Kolho, Martti Färkkilâ, Taina Sipponen	144

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact